A new study led by researchers at the University of Maryland School of Medicine and the Malawi-Liverpool Wellcome Trust has shown that a single dose of the typhoid conjugate vaccine (Typbar TCV®) provides lasting efficacy in preventing typhoid fever in children aged 9 months to 12 years. Published in The Lancet, the phase 3 clinical study enrolled over 28,000 healthy children in Malawi, with half receiving the TCV and the other half a control vaccine. Over more than four years, 24 children in the TCV group and 110 in the control group developed typhoid, demonstrating a 78.3% efficacy for the TCV. The vaccine remained effective across all age groups and showed only a 1.3% annual decrease in efficacy. Typhoid fever, which affects over nine million people annually and causes at least 110,000 deaths, is a severe bacterial infection spread through contaminated food and water. The study’s findings highlight the potential of TCVs to control and possibly eliminate typhoid fever in endemic regions.
Single dose typhoid conjugate vaccine provides lasting efficacy in children
< 1 min read
